Search

Your search keyword '"Kommoss, Stefan"' showing total 675 results
Start Over Author "Kommoss, Stefan"
675 results on '"Kommoss, Stefan"'

201. A prospective randomized experimental study to investigate the peritoneal adhesion formation after waterjet injection and argon plasma coagulation (HybridAPC) in a rat model

Author

Kraemer, Bernhard, primary, Scharpf, Marcus, additional, Keckstein, Simon, additional, Dippon, Julia, additional, Tsaousidis, Christos, additional, Brunecker, Kristin, additional, Enderle, Markus Dominik, additional, Neugebauer, Alexander, additional, Nuessle, Daniela, additional, Fend, Falko, additional, Brucker, Sara, additional, Taran, Florin-Andrei, additional, Kommoss, Stefan, additional, and Rothmund, Ralf, additional

Published
2018
Full Text
View/download PDF

202. Atypical course of a caesarean scar pregnancy.

Author

Schlammerl, Katharina, Kommoss, Stefan, Krämer, Bernhard, Hoopmann, Markus, and Bachmann, Cornelia

Subjects
*PREGNANCY, *SCARS, *DOPPLER ultrasonography, *DATA editing, *TRANSVAGINAL ultrasonography
Abstract

Ultrasound revealed a vital pregnancy in the caesarean scar while large parts of the trophoblast have grown into it reaching up to the serosa ( -HCGlevel: 26873U/l). The 36-year old patient presented first with a caesarean scar pregnancy (vital) at 7 weeks of gestation. At the same time, a discrete progression of the chorionic cavity was noted (size: 3.4 × 3.2 × 2.3 cm), while the -HCGlevel dropped to 2348U/l. Another 2 weeks later, the ultrasound check-up detected no more embryonic structures, a significantly reduced blood flow and a thinned trophoblast ring. [Extracted from the article]

Published
2023
Full Text
View/download PDF

203. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Author

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, Ellen L, Block, Matthew S, Kalli, Kimberly R, Vierkant, Robert A, Chen, Wenqian, Fogarty, Zachary C, Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L, Jensen, Allan, Osorio, Ana, Hartkopf, Andreas, Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M, Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y, Fridley, Brooke L, McCauley, Bryan M, Kennedy, Catherine J, Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B, Tiezzi, Daniel G, Wachter, David L, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H, Kelley, Joseph L, de Andrade, Jurandyr M, Robles-Díaz, Luis, Intermaggio, Maria P, Widschwendter, Martin, Beckmann, Matthias W, Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R, Rambau, Peter F, Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P, Ness, Roberta B, Orsulic, Sandra, Brucker, Sara Y, Johnatty, Sharon E, Longacre, Teri A, Ursula, Eilber, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S, Anna, deFazio, Staebler, Annette, Karlan, Beth Y, Gilks, Blake, Bowtell, David D, Høgdall, Estrid, Candido dos Reis, Francisco J, Steed, Helen, Campbell, Ian G, Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, García, María José, Fasching, Peter A, Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K, Menon, Usha, Brenton, James D, Pharoah, Paul DP, Chenevix-Trench, Georgia, Huntsman, David G, Winham, Stacey J, Köbel, Martin, Ramus, Susan J, Ovarian Tumor Tissue Analysis (OTTA) Consortium, Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, Ellen L, Block, Matthew S, Kalli, Kimberly R, Vierkant, Robert A, Chen, Wenqian, Fogarty, Zachary C, Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L, Jensen, Allan, Osorio, Ana, Hartkopf, Andreas, Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M, Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y, Fridley, Brooke L, McCauley, Bryan M, Kennedy, Catherine J, Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B, Tiezzi, Daniel G, Wachter, David L, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H, Kelley, Joseph L, de Andrade, Jurandyr M, Robles-Díaz, Luis, Intermaggio, Maria P, Widschwendter, Martin, Beckmann, Matthias W, Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R, Rambau, Peter F, Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P, Ness, Roberta B, Orsulic, Sandra, Brucker, Sara Y, Johnatty, Sharon E, Longacre, Teri A, Ursula, Eilber, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S, Anna, deFazio, Staebler, Annette, Karlan, Beth Y, Gilks, Blake, Bowtell, David D, Høgdall, Estrid, Candido dos Reis, Francisco J, Steed, Helen, Campbell, Ian G, Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, García, María José, Fasching, Peter A, Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K, Menon, Usha, Brenton, James D, Pharoah, Paul DP, Chenevix-Trench, Georgia, Huntsman, David G, Winham, Stacey J, Köbel, Martin, and Ramus, Susan J

Abstract

ImportanceCytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.ObjectiveTo define the prognostic role of CD8+ TILs in epithelial ovarian cancer.Design, setting, and participantsThis was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.ExposuresFollowing immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.Main outcomes and measuresOverall survival time.ResultsThe final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+

Published
2017

204. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

Author

Harter, Philipp, Hauke, Jan, Heitz, Florian, Reuss, Alexander, Kommoss, Stefan, Marme, Frederik, Heimbach, Andre, Prieske, Katharina, Richters, Lisa, Burges, Alexander, Neidhardt, Guido, de Gregorio, Nikolaus, El-Balat, Ahmed, Hilpert, Felix, Meier, Werner, Kimmig, Rainer, Kast, Karin, Sehouli, Jalid, Baumann, Klaus, Jackisch, Christian, Park-Simon, Tjoung-Won, Hanker, Lars, Kroeber, Sandra, Pfisterer, Jacobus, Gevensleben, Heidrun, Schnelzer, Andreas, Dietrich, Dimo, Neunhoeffer, Tanja, Krockenberger, Mathias, Brucker, Sara Y., Nuernberg, Peter, Thiele, Holger, Altmueller, Janine, Lamla, Josefin, Elser, Gabriele, du Bois, Andreas, Hahnen, Eric, Schmutzler, Rita, Harter, Philipp, Hauke, Jan, Heitz, Florian, Reuss, Alexander, Kommoss, Stefan, Marme, Frederik, Heimbach, Andre, Prieske, Katharina, Richters, Lisa, Burges, Alexander, Neidhardt, Guido, de Gregorio, Nikolaus, El-Balat, Ahmed, Hilpert, Felix, Meier, Werner, Kimmig, Rainer, Kast, Karin, Sehouli, Jalid, Baumann, Klaus, Jackisch, Christian, Park-Simon, Tjoung-Won, Hanker, Lars, Kroeber, Sandra, Pfisterer, Jacobus, Gevensleben, Heidrun, Schnelzer, Andreas, Dietrich, Dimo, Neunhoeffer, Tanja, Krockenberger, Mathias, Brucker, Sara Y., Nuernberg, Peter, Thiele, Holger, Altmueller, Janine, Lamla, Josefin, Elser, Gabriele, du Bois, Andreas, Hahnen, Eric, and Schmutzler, Rita

Abstract

Background Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in BRCA1/2 in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated. Methods Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PMS2, PTEN, PALB2, RAD51C, RAD51D, STK11, TP53) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history. Results In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16-93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the BRCA1 (15.5%), BRCA2 (5.5%), RAD51C (2.5%) and PALB2 (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients >= 60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of de

Published
2017

205. BRCA-like classification in ovarian cancer: Results from the AGO-TRi-trial.

Author

Richters, Lisa Katharina, Schouten, Philip C., Kommoss, Stefan, Hauke, Jan, Burges, Alexander, Dietrich, Dimo, Ei-Balat, Ahmed, Hilpert, Felix, Kluin, Roel, Heubner, Martin Leonhard, Kast, Karin, Heimbach, Andre, Braicu, Elena Ioana, Schmidt, Sandra, Baumann, Klaus H., Jackisch, Christian, Linn, Sabine C., Schmutzler, Rita K., Harter, Philipp, Hahnen, Eric, Richters, Lisa Katharina, Schouten, Philip C., Kommoss, Stefan, Hauke, Jan, Burges, Alexander, Dietrich, Dimo, Ei-Balat, Ahmed, Hilpert, Felix, Kluin, Roel, Heubner, Martin Leonhard, Kast, Karin, Heimbach, Andre, Braicu, Elena Ioana, Schmidt, Sandra, Baumann, Klaus H., Jackisch, Christian, Linn, Sabine C., Schmutzler, Rita K., Harter, Philipp, and Hahnen, Eric

Published
2017

206. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

Author

Galli, Alvaro, Harter, Philipp, Hauke, Jan, Heitz, Florian, Reuss, Alexander, Kommoss, Stefan, Marmé, Frederik, Heimbach, André, Prieske, Katharina, Richters, Lisa, Burges, Alexander, Neidhardt, Guido, Gregorio, Nikolaus de, Balat, Ahmed el, Hilpert, Felix, Meier, Werner, Kimmig, Rainer, Kast, Karin, Sehouli, Jalid, Baumann, Klaus, Jackisch, Christian, Park-Simon, Tjoung-Won, Hanker, Lars, Kröber, Sandra, Pfisterer, Jacobus, Gevensleben, Heidrun, Schnelzer, Andreas, Dietrich, Dimo, Neunhöffer, Tanja, Krockenberger, Mathias Heinric, Brucker, Sara, Nürnberg, Peter, Thiele, Holger, Altmüller, Janine, Lamla, Josefin, Elser, Gabriele, Du Bois, Andreas, Hahnen, Eric Thomas, Schmutzler, Rita Katharina, Galli, Alvaro, Harter, Philipp, Hauke, Jan, Heitz, Florian, Reuss, Alexander, Kommoss, Stefan, Marmé, Frederik, Heimbach, André, Prieske, Katharina, Richters, Lisa, Burges, Alexander, Neidhardt, Guido, Gregorio, Nikolaus de, Balat, Ahmed el, Hilpert, Felix, Meier, Werner, Kimmig, Rainer, Kast, Karin, Sehouli, Jalid, Baumann, Klaus, Jackisch, Christian, Park-Simon, Tjoung-Won, Hanker, Lars, Kröber, Sandra, Pfisterer, Jacobus, Gevensleben, Heidrun, Schnelzer, Andreas, Dietrich, Dimo, Neunhöffer, Tanja, Krockenberger, Mathias Heinric, Brucker, Sara, Nürnberg, Peter, Thiele, Holger, Altmüller, Janine, Lamla, Josefin, Elser, Gabriele, Du Bois, Andreas, Hahnen, Eric Thomas, and Schmutzler, Rita Katharina

Abstract

Background: Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in BRCA1/2 in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated. Methods: Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PMS2, PTEN, PALB2, RAD51C, RAD51D, STK11, TP53) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history. Results: In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16–93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the BRCA1 (15.5%), BRCA2 (5.5%), RAD51C (2.5%) and PALB2 (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients ≥60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of d

Published
2017

207. Corrigendum to 'Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group'

Author

du Bois, Andreas, Ewald-Riegler, Nina, de Gregorio, Nikolaus, Reuss, Alexander, Mahner, Sven, Fotopoulou, Christina, Kommoss, Friedrich, Schmalfeldt, Barbara, Hilpert, Felix, Fehm, Tanja, Burges, Alexander, Meier, Werner, Hillemanns, Peter, Hanker, Lars, Hasenburg, Annette, Strauss, Hans-Georg, Hellriegel, Martin, Wimberger, Pauline, Keyver-Paik, Mignon-Denise, Baumann, Klaus, Canzler, Ulrich, Wollschlaeger, Kerstin, Forner, Dirk, Pfisterer, Jacobus, Schröder, Willibald, Münstedt, Karsten, Richter, Barbara, Kommoss, Stefan, and Hauptmann, Steffen

Subjects
Medizin
Published
2016

208. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

Author

Southey, Melissa C, Goldgar, David E, Winqvist, Robert, Pylkäs, Katri, Couch, Fergus, Tischkowitz, Marc, Foulkes, William D, Dennis, Joe, Michailidou, Kyriaki, van Rensburg, Elizabeth J, Heikkinen, Tuomas, Nevanlinna, Heli, Hopper, John L, Dörk, Thilo, Claes, Kathleen Bm, Reis-Filho, Jorge, Teo, Zhi Ling, Radice, Paolo, Catucci, Irene, Peterlongo, Paolo, Tsimiklis, Helen, Odefrey, Fabrice A, Dowty, James G, Schmidt, Marjanka K, Broeks, Annegien, Hogervorst, Frans B, Verhoef, Senno, Carpenter, Jane, Clarke, Christine, Scott, Rodney J, Fasching, Peter A, Haeberle, Lothar, Ekici, Arif B, Beckmann, Matthias W, Peto, Julian, Dos-Santos-Silva, Isabel, Fletcher, Olivia, Johnson, Nichola, Bolla, Manjeet K, Sawyer, Elinor J, Tomlinson, Ian, Kerin, Michael J, Miller, Nicola, Marme, Federik, Burwinkel, Barbara, Yang, Rongxi, Guénel, Pascal, Truong, Thérèse, Menegaux, Florence, Sanchez, Marie, Bojesen, Stig, Nielsen, Sune F, Flyger, Henrik, Benitez, Javier, Zamora, M Pilar, Perez, Jose Ignacio Arias, Menéndez, Primitiva, Anton-Culver, Hoda, Neuhausen, Susan, Ziogas, Argyrios, Clarke, Christina A, Brenner, Hermann, Arndt, Volker, Stegmaier, Christa, Brauch, Hiltrud, Brüning, Thomas, Ko, Yon-Dschun, Muranen, Taru A, Aittomäki, Kristiina, Blomqvist, Carl, Bogdanova, Natalia V, Antonenkova, Natalia N, Lindblom, Annika, Margolin, Sara, Mannermaa, Arto, Kataja, Vesa, Kosma, Veli-Matti, Hartikainen, Jaana M, Spurdle, Amanda B, Investigators, kConFab, Australian Ovarian Cancer Study Group, Wauters, Els, Smeets, Dominiek, Beuselinck, Benoit, Floris, Giuseppe, Chang-Claude, Jenny, Rudolph, Anja, Seibold, Petra, Flesch-Janys, Dieter, Olson, Janet E, Vachon, Celine, Pankratz, Vernon S, McLean, Catriona, Haiman, Christopher A, Henderson, Brian E, Schumacher, Fredrick, Le Marchand, Loic, Kristensen, Vessela, Alnæs, Grethe Grenaker, Zheng, Wei, Hunter, David J, Lindstrom, Sara, Hankinson, Susan E, Kraft, Peter, Andrulis, Irene, Knight, Julia A, Glendon, Gord, Mulligan, Anna Marie, Jukkola-Vuorinen, Arja, Grip, Mervi, Kauppila, Saila, Devilee, Peter, Tollenaar, Robert AEM, Seynaeve, Caroline, Hollestelle, Antoinette, Garcia-Closas, Montserrat, Figueroa, Jonine, Chanock, Stephen J, Lissowska, Jolanta, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael, Eccles, Diana M, Rafiq, Sajjad, Tapper, William J, Gerty, Sue M, Hooning, Maartje J, Martens, John WM, Collée, J Margriet, Tilanus-Linthorst, Madeleine, Hall, Per, Li, Jingmei, Brand, Judith S, Humphreys, Keith, Cox, Angela, Reed, Malcolm WR, Luccarini, Craig, Baynes, Caroline, Dunning, Alison M, Hamann, Ute, Torres, Diana, Ulmer, Hans Ulrich, Rüdiger, Thomas, Jakubowska, Anna, Lubinski, Jan, Jaworska, Katarzyna, Durda, Katarzyna, Slager, Susan, Toland, Amanda E, Ambrosone, Christine B, Yannoukakos, Drakoulis, Swerdlow, Anthony, Ashworth, Alan, Orr, Nick, Jones, Michael, González-Neira, Anna, Pita, Guillermo, Alonso, M Rosario, Álvarez, Nuria, Herrero, Daniel, Tessier, Daniel C, Vincent, Daniel, Bacot, Francois, Simard, Jacques, Dumont, Martine, Soucy, Penny, Eeles, Rosalind, Muir, Kenneth, Wiklund, Fredrik, Gronberg, Henrik, Schleutker, Johanna, Nordestgaard, Børge G, Weischer, Maren, Travis, Ruth C, Neal, David, Donovan, Jenny L, Hamdy, Freddie C, Khaw, Kay-Tee, Stanford, Janet L, Blot, William J, Thibodeau, Stephen, Schaid, Daniel J, Kelley, Joseph L, Maier, Christiane, Kibel, Adam S, Cybulski, Cezary, Cannon-Albright, Lisa, Butterbach, Katja, Park, Jong, Kaneva, Radka, Batra, Jyotsna, Teixeira, Manuel R, Kote-Jarai, Zsofia, Olama, Ali Amin Al, Benlloch, Sara, Renner, Stefan P, Hartmann, Arndt, Hein, Alexander, Ruebner, Matthias, Lambrechts, Diether, Van Nieuwenhuysen, Els, Vergote, Ignace, Lambretchs, Sandrina, Doherty, Jennifer A, Rossing, Mary Anne, Nickels, Stefan, Eilber, Ursula, Wang-Gohrke, Shan, Odunsi, Kunle, Sucheston-Campbell, Lara E, Friel, Grace, Lurie, Galina, Killeen, Jeffrey L, Wilkens, Lynne R, Goodman, Marc T, Runnebaum, Ingo, Hillemanns, Peter A, Pelttari, Liisa M, Butzow, Ralf, Modugno, Francesmary, Edwards, Robert P, Ness, Roberta B, Moysich, Kirsten B, du Bois, Andreas, Heitz, Florian, Harter, Philipp, Kommoss, Stefan, Karlan, Beth Y, Walsh, Christine, Lester, Jenny, Jensen, Allan, Kjaer, Susanne Krüger, Høgdall, Estrid, Peissel, Bernard, Bonanni, Bernardo, Bernard, Loris, Goode, Ellen L, Fridley, Brooke L, Vierkant, Robert A, Cunningham, Julie M, Larson, Melissa C, Fogarty, Zachary C, Kalli, Kimberly R, Liang, Dong, Lu, Karen H, Hildebrandt, Michelle AT, Wu, Xifeng, Levine, Douglas A, Dao, Fanny, Bisogna, Maria, Berchuck, Andrew, Iversen, Edwin S, Marks, Jeffrey R, Akushevich, Lucy, Cramer, Daniel W, Schildkraut, Joellen, Terry, Kathryn L, Poole, Elizabeth M, Stampfer, Meir, Tworoger, Shelley S, Bandera, Elisa V, Orlow, Irene, Olson, Sara H, Bjorge, Line, Salvesen, Helga B, van Altena, Anne M, Aben, Katja KH, Kiemeney, Lambertus A, Massuger, Leon FAG, Pejovic, Tanja, Bean, Yukie, Brooks-Wilson, Angela, Kelemen, Linda E, Cook, Linda S, Le, Nhu D, Górski, Bohdan, Gronwald, Jacek, Menkiszak, Janusz, Høgdall, Claus K, Lundvall, Lene, Nedergaard, Lotte, Engelholm, Svend Aage, Dicks, Ed, Tyrer, Jonathan, Campbell, Ian, McNeish, Iain, Paul, James, Siddiqui, Nadeem, Glasspool, Rosalind, Whittemore, Alice S, Rothstein, Joseph H, McGuire, Valerie, Sieh, Weiva, Cai, Hui, Shu, Xiao-Ou, Teten, Rachel T, Sutphen, Rebecca, McLaughlin, John R, Narod, Steven A, Phelan, Catherine M, Monteiro, Alvaro N, Fenstermacher, David, Lin, Hui-Yi, Permuth, Jennifer B, Sellers, Thomas A, Chen, Y Ann, Tsai, Ya-Yu, Chen, Zhihua, Gentry-Maharaj, Aleksandra, Gayther, Simon A, Ramus, Susan J, Menon, Usha, Wu, Anna H, Pearce, Celeste L, Van Den Berg, David, Pike, Malcolm C, Dansonka-Mieszkowska, Agnieszka, Plisiecka-Halasa, Joanna, Moes-Sosnowska, Joanna, Kupryjanczyk, Jolanta, Pharoah, Paul Dp, Song, Honglin, Winship, Ingrid, Chenevix-Trench, Georgia, Giles, Graham G, Tavtigian, Sean V, Easton, Doug F, Milne, Roger L, Clinical Genetics, Neurology, Medical Oncology, Surgery, Erasmus MC other, Clinicum, Department of Obstetrics and Gynecology, Medicum, Kristiina Aittomäki / Principal Investigator, Department of Medical and Clinical Genetics, Department of Oncology, Department of Pathology, HUS Gynecology and Obstetrics, Tischkowitz, Marc [0000-0002-7880-0628], Dennis, Joe [0000-0003-4591-1214], Dunning, Alison [0000-0001-6651-7166], Khaw, Kay-Tee [0000-0002-8802-2903], Amin Al Olama, Ali [0000-0002-7178-3431], Dicks, Ed [0000-0002-0617-0401], Tyrer, Jonathan [0000-0003-3724-4757], Pharoah, Paul [0000-0001-8494-732X], Song, Honglin [0000-0001-5076-7371], Easton, Douglas [0000-0003-2444-3247], and Apollo - University of Cambridge Repository

Subjects
0301 basic medicine, Oncology, Male, Ataxia Telangiectasia Mutated Proteins, prostate-cancer, Prostate cancer, 0302 clinical medicine, brca1, Medizinische Fakultät, Medicine and Health Sciences, skin and connective tissue diseases, Genetics (clinical), Ovarian Neoplasms, education.field_of_study, brca2-interacting protein, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], 1184 Genetics, developmental biology, physiology, Nuclear Proteins, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], 3. Good health, PROSTATE-CANCER, Cancer: prostate, Multicenter Study, ovarian-cancer, Centre for Surgical Research, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, ovary [Cancer], Female, Fanconi Anemia Complementation Group N Protein, metaanalysis, Risk, medicine.medical_specialty, SUSCEPTIBILITY LOCI, Population, 3122 Cancers, cancer predisposition, Breast Neoplasms, OVARIAN-CANCER, BRCA2-INTERACTING PROTEIN, Cancer: ovary, 03 medical and health sciences, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, prostate [Cancer], medicine, Cancer Genetics, Genetics, Journal Article, breast [Cancer], BREAST-CANCER, Humans, Genetic Predisposition to Disease, ddc:610, education, gene, CHEK2, FAMILY REGISTRY, METAANALYSIS, breast-cancer, Genetic Association Studies, business.industry, MUTATIONS, Cancer: breast, Tumor Suppressor Proteins, Case-control study, Cancer, Prostatic Neoplasms, medicine.disease, BRCA1, mutations, GENE, susceptibility loci, Checkpoint Kinase 2, 030104 developmental biology, Relative risk, Case-Control Studies, Mutation, family registry, Ovarian cancer, business
Abstract

Background: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study.Methods: We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant.Results: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10−5), PALB2 c.3113G>A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10−8) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26 (95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5) and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants.Conclusions: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.

Published
2016

209. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

Author

Harter, Philipp, primary, Hauke, Jan, additional, Heitz, Florian, additional, Reuss, Alexander, additional, Kommoss, Stefan, additional, Marmé, Frederik, additional, Heimbach, André, additional, Prieske, Katharina, additional, Richters, Lisa, additional, Burges, Alexander, additional, Neidhardt, Guido, additional, de Gregorio, Nikolaus, additional, El-Balat, Ahmed, additional, Hilpert, Felix, additional, Meier, Werner, additional, Kimmig, Rainer, additional, Kast, Karin, additional, Sehouli, Jalid, additional, Baumann, Klaus, additional, Jackisch, Christian, additional, Park-Simon, Tjoung-Won, additional, Hanker, Lars, additional, Kröber, Sandra, additional, Pfisterer, Jacobus, additional, Gevensleben, Heidrun, additional, Schnelzer, Andreas, additional, Dietrich, Dimo, additional, Neunhöffer, Tanja, additional, Krockenberger, Mathias, additional, Brucker, Sara Y., additional, Nürnberg, Peter, additional, Thiele, Holger, additional, Altmüller, Janine, additional, Lamla, Josefin, additional, Elser, Gabriele, additional, du Bois, Andreas, additional, Hahnen, Eric, additional, and Schmutzler, Rita, additional

Published
2017
Full Text
View/download PDF

210. Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes

Author

Kommoss, Stefan, primary, Winterhoff, Boris, additional, Oberg, Ann L., additional, Konecny, Gottfried E., additional, Wang, Chen, additional, Riska, Shaun M., additional, Fan, Jian-Bing, additional, Maurer, Matthew J., additional, April, Craig, additional, Shridhar, Viji, additional, Kommoss, Friedrich, additional, du Bois, Andreas, additional, Hilpert, Felix, additional, Mahner, Sven, additional, Baumann, Klaus, additional, Schroeder, Willibald, additional, Burges, Alexander, additional, Canzler, Ulrich, additional, Chien, Jeremy, additional, Embleton, Andrew C., additional, Parmar, Mahesh, additional, Kaplan, Richard, additional, Perren, Timothy, additional, Hartmann, Lynn C., additional, Goode, Ellen L., additional, Dowdy, Sean C., additional, and Pfisterer, Jacobus, additional

Published
2017
Full Text
View/download PDF

211. Abstract 2215: Detection of novel markers of transitional cell carcinoma of the ovary, the TCC-like variant of high grade serous carcinoma, using proteomics and immunohistochemistry

Author

Tessier-Cloutier, Basile, primary, Magrill, Jamie, additional, Kommoss, Stefan, additional, Gilks, Blake C., additional, Huntsman, David G., additional, Cochrane, Dawn R., additional, Talhouk, Aline, additional, Soslow, Robert, additional, Morin, Gregg B., additional, Hughes, Chris J., additional, Karnezis, Anthony N., additional, Chow, Christine, additional, Cheng, Angela S., additional, Bois, Andreas du, additional, Pfisterer, Jacobus, additional, and Kommoss, Friedrich, additional

Published
2017
Full Text
View/download PDF

212. BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial.

Author

Richters, Lisa Katharina, primary, Schouten, Philip C., additional, Kommoss, Stefan, additional, Hauke, Jan, additional, Burges, Alexander, additional, Dietrich, Dimo, additional, El-Balat, Ahmed, additional, Hilpert, Felix, additional, Kluin, Roel, additional, Heubner, Martin Leonhard, additional, Kast, Karin, additional, Heimbach, André, additional, Braicu, Elena Ioana, additional, Schmidt, Sandra, additional, Baumann, Klaus H., additional, Jackisch, Christian, additional, Linn, Sabine C., additional, Schmutzler, Rita K., additional, Harter, Philipp, additional, and Hahnen, Eric, additional

Published
2017
Full Text
View/download PDF

214. Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles

Author

Magrill, Jamie, Karnezis, Anthony N., Tessier-Cloutier, Basile, Talhouk, Aline, Kommoss, Stefan, Cochrane, Dawn, Chow, Christine, Cheng, Angela, Soslow, Robert, Hauptmann, Steffen, du Bois, Andreas, Pfisterer, Jacobus, Gilks, C. Blake, Huntsman, David G., and Kommoss, Friedrich

Abstract

Tubo-ovarian transitional cell carcinoma (TCC) is grouped with high-grade serous carcinoma (HGSC) in the current World Health Organization classification. TCC is associated with BRCA mutations and a better prognosis compared with HGSC. Previous papers examining the immunohistochemical features of TCC have studied limited numbers of samples. No marker reflecting the biological difference between TCC and HGSC is known. We collected a large cohort of TCC to determine whether TCC and HGSC could be distinguished by immunohistochemistry. A tissue microarray was built from 89 TCC and a control cohort of 232 conventional HGSC. Immunohistochemistry was performed, scored, and statistically analyzed for routine markers of HGSC and urothelial tumors: PAX8, WT1, p53, p16, ER, p63, and GATA3. Using scoring cutoffs commonly employed in clinical practice, the immunohistochemical profile of TCC was indistinguishable from HGSC for all markers. However, more detailed scoring criteria revealed statistically significant differences between the 2 groups of tumors with respect to ER, PAX8, and WT1. HGSC showed more diffuse and intense staining for PAX8 (P=0.004 and 0.001, respectively) and WT1 (P=0.002 and 0.002, respectively); conversely, TCC showed more intense staining for ER (P=0.007). TCC and HGSC therefore show subtle differences in their immunohistochemical profiles which might reflect underlying (epi)genetic differences. Further studies using proteomic analysis will focus on the identification of differentially expressed proteins that might serve as markers of TCC-like differentiation, which could help explain biologic differences between TCC and HGSC and might identify other cases of HGSC with a better prognosis.

Published
2019
Full Text
View/download PDF

215. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.

Author

Fischer, Anna Katharina, Pham, Deborah L., Bösmüller, Hans, Lengerke, Claudia, Wagner, Philipp, Bachmann, Cornelia, Beschorner, Christine, Perner, Sven, Kommoss, Stefan, Fend, Falko, and Staebler, Annette

Abstract

Recent studies have shown that re-expression of stem cell factors contribute to pathogenesis, therapy resistance, and recurrent disease in ovarian carcinomas. In this study, we compare the expression and co-expression of stem cell markers ALDH1 and SOX2 in different types of serous ovarian tumors. A total of 215 serous ovarian tumors (161 high-grade serous carcinomas (HGSC), 17 low-grade serous carcinomas (LGSC), 37 atypical proliferative serous tumors (APST)), and 10 cases of serous tubal intraepithelial carcinoma (STIC) were analyzed. Double immunostaining experiments addressed the association of cell proliferation (Ki67) with ALDH1 and the potential co-expression of SOX2 and ALDH1. The prognostic effect was analyzed in the cohort of HGSC. Expression of ALDH1and/or SOX2 was detected with increased frequency in HGSC (88.8%), compared with LGSC (70.5%) and APST (36.4%), while ALDH1 alone was significantly more frequently expressed in LGSC. The majority of all tumor types showed expression of ALDH1 and SOX2 in different cells. Only a minority of HGSC (4.6%) and STIC (20%) showed SOX2/ALDH1 co-expression in > 10% of tumor cells. Double staining also revealed that ALDH1 is associated with the non-proliferating Ki67-negative fraction consistent with a stem cell phenotype. Co-expression of ALDH1 and SOX2 or ALDH1 and Ki67 has no effect on survival. Expression of stem cell factors ALDH1 and/or SOX2 shows increased frequency in high-grade serous ovarian carcinomas compared to low-grade carcinomas and borderline tumors, supporting the concept that stem cell markers play different biological roles in low-grade versus high-grade serous neoplasia of the ovary. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

216. Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.

Author

Heublein, Sabine, Anglesio, Michael S., Marmé, Frederik, and Kommoss, Stefan

Subjects
FIBROBLAST growth factor receptors, CA 125 test, OVARIAN cancer, OVARIAN diseases, PROPORTIONAL hazards models, IMMUNOHISTOCHEMISTRY
Abstract

Purpose: Fibroblast Growth Factor Receptor 4 (FGFR4) was proposed to hold prognostic significance in high-grade serous ovarian carcinoma (HGSOC). However, information on this deriving from large, representative patient panels is still missing, though such data would be indispensable to validate suitability of FGFR4 as prognostic marker or even pharmacological target. Methods: 1063 ovarian cancer cases were included in this study. Immunohistochemistry (IHC) was performed using two different anti-FGFR4 specific antibodies (HPA027273, sc-124) on an automated staining system. IHC data of both FGFR4 antibodies were available from 995 cases. FGFR4 immunostaining was correlated to prognostic factors including survival using uni- and multivariate proportional hazard models. Results: FGFR4 was positively associated with advanced FIGO stage, high grade and presence of residual disease. When progression free (PFS) of FGFR4 negative vs. positive patients was compared, patients scored as FGFR4 positive had significantly shortened PFS as compared to those that stained negative. All associations of FGFR4 and shortened PFS were lost during multivariate testing. No significant associations were found in terms of OS. Conclusions: We were not able to confirm FGFR4 as an independent negative prognosticator as described before. However, FGFR4 was highly prevalent in those cases harboring residual disease after debulking surgery. Since especially patients that could only be debulked sub-optimally may benefit from targeted adjuvant treatment, tyrosine kinase inhibitors targeting FGFRs might turn out to be an interesting future treatment option. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

218. What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Author

Schmalfeldt, Barbara, Brambs, Christine, Burges, Alexander, El-Balat, Ahmed, Emons, Günter, Fink, Daniel, Fotopoulou, Christina, Gropp-Meier, Martina, Hanker, Lars-Christian, Harter, Philipp, Hasenburg, Annette, Hauptmann, Steffen, Hilpert, Felix, Kimmig, Rainer, Kommoss, Stefan, Kurzeder, Christian, Mahner, Sven, Marmé, Frederik, Mayr, Doris, and Meier, Werner

Subjects
GYNECOLOGIC cancer, OVARIAN cancer, OVARIAN epithelial cancer, LYMPHADENECTOMY
Published
2019
Full Text
View/download PDF

220. Incidence of gernnline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1).

Author

Harter, Philipp, Hauke, Jan, Heitz, Florian, Reuss, Alexander, Kommoss, Stefan, Marme, Frederik, Heimbach, Andre, Prieske, Katharina, Richters, Lisa Katharina, Burges, Alexander, Neidhardt, Guido, de Gregorio, Nikolaus, El-Balat, Ahmed, Hilpert, Felix, Meier, Werner, Heubner, Martin Leonhard, Kast, Karin, Braicu, Ioana, Hahnen, Eric, Schmutzler, Rita K., Harter, Philipp, Hauke, Jan, Heitz, Florian, Reuss, Alexander, Kommoss, Stefan, Marme, Frederik, Heimbach, Andre, Prieske, Katharina, Richters, Lisa Katharina, Burges, Alexander, Neidhardt, Guido, de Gregorio, Nikolaus, El-Balat, Ahmed, Hilpert, Felix, Meier, Werner, Heubner, Martin Leonhard, Kast, Karin, Braicu, Ioana, Hahnen, Eric, and Schmutzler, Rita K.

Published
2016

221. Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study).

Author

Hahnen, Eric, Baumann, Klaus H., Heimbach, Andre, Reuss, Alexander, Jackisch, Christian, Hauke, Jan, Park-Simon, Tjoung-Won, Richters, Lisa Katharina, Hanker, Lars Christian, Kroeber, Sandra, Pfisterer, Jacobus, Gevensleben, Heidrun, Schnelzer, Andreas, Dietrich, Dimo, Schneider, Stephanie, Kommoss, Stefan, Marme, Frederic, Prieske, Katharina, Schmutzler, Rita K., Harter, Philipp, Hahnen, Eric, Baumann, Klaus H., Heimbach, Andre, Reuss, Alexander, Jackisch, Christian, Hauke, Jan, Park-Simon, Tjoung-Won, Richters, Lisa Katharina, Hanker, Lars Christian, Kroeber, Sandra, Pfisterer, Jacobus, Gevensleben, Heidrun, Schnelzer, Andreas, Dietrich, Dimo, Schneider, Stephanie, Kommoss, Stefan, Marme, Frederic, Prieske, Katharina, Schmutzler, Rita K., and Harter, Philipp

Published
2016

222. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.

Author

Vogel, Rachel Isaksson, Vogel, Rachel Isaksson, Pulver, Tanya, Heilmann, Wiebke, Mooneyham, Ashley, Mullany, Sally, Zhao, Xianda, Shahi, Maryam, Richter, James, Klein, Molly, Chen, Liqiang, Ding, Rui, Konecny, Gottfried, Kommoss, Stefan, Winterhoff, Boris, Ghebre, Rahel, Bazzaro, Martina, Vogel, Rachel Isaksson, Vogel, Rachel Isaksson, Pulver, Tanya, Heilmann, Wiebke, Mooneyham, Ashley, Mullany, Sally, Zhao, Xianda, Shahi, Maryam, Richter, James, Klein, Molly, Chen, Liqiang, Ding, Rui, Konecny, Gottfried, Kommoss, Stefan, Winterhoff, Boris, Ghebre, Rahel, and Bazzaro, Martina

Abstract

Endometrial adenocarcinoma is the most common gynecologic malignancy in the United States. Most endometrial cancer cases are diagnosed at an early stage and have good prognosis. Unfortunately a subset of patients with early stage and low grade disease experience recurrence for reasons that remain unclear. Recurrence is often accompanied by chemoresistance and high mortality.Deubiquitinating enzymes (DUBs) are key components of the ubiquitin-dependent protein degradation pathway and act as master regulators in a number of metabolic processes including cell growth, differentiation, and apoptosis. DUBs have been shown to be upregulated in a number of human cancers and their aberrant activity has been linked to cancer progression, initiation and onset of chemoresistance. Thus, selective inhibition of DUBs has been proposed as a targeted therapy for cancer treatment.This study suggests the DUB USP14 as a promising biomarker for stratifying endometrial cancer patients at diagnosis based on their risk of recurrence. Further USP14 is expressed along with the marker of proliferation Ki67 in endometrial cancer cells in situ. Lastly, pharmacological targeting of USP14 with the FDA approved small-molecule inhibitor VLX1570, decreases cell viability in chemotherapy resistant endometrial cancer cells with a mechanism consistent with cell cycle arrest and caspase-3 mediated apoptosis.

Published
2016

223. L1CAM: amending the “low-risk” category in endometrial carcinoma

Author

Kommoss, Felix, primary, Kommoss, Friedrich, additional, Grevenkamp, Friederike, additional, Bunz, Anne-Kathrin, additional, Taran, Florin-Andrei, additional, Fend, Falko, additional, Brucker, Sara Y., additional, Wallwiener, Diethelm, additional, Schönfisch, Birgitt, additional, Greif, Karen, additional, Lax, Sigurd, additional, Staebler, Annette, additional, and Kommoss, Stefan, additional

Published
2016
Full Text
View/download PDF

225. Corrigendum to “Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group” [Eur J Cancer 49 (2013) 1905–1914]

Author

du Bois, Andreas, primary, Ewald-Riegler, Nina, additional, de Gregorio, Nikolaus, additional, Reuss, Alexander, additional, Mahner, Sven, additional, Fotopoulou, Christina, additional, Kommoss, Friedrich, additional, Schmalfeldt, Barbara, additional, Hilpert, Felix, additional, Fehm, Tanja, additional, Burges, Alexander, additional, Meier, Werner, additional, Hillemanns, Peter, additional, Hanker, Lars, additional, Hasenburg, Annette, additional, Strauss, Hans-Georg, additional, Hellriegel, Martin, additional, Wimberger, Pauline, additional, Keyver-Paik, Mignon-Denise, additional, Baumann, Klaus, additional, Canzler, Ulrich, additional, Wollschlaeger, Kerstin, additional, Forner, Dirk, additional, Pfisterer, Jacobus, additional, Schröder, Willibald, additional, Münstedt, Karsten, additional, Richter, Barbara, additional, Kommoss, Stefan, additional, and Hauptmann, Steffen, additional

Published
2016
Full Text
View/download PDF

227. Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype

Author

McConechy, Melissa K., primary, Färkkilä, Anniina, additional, Horlings, Hugo M., additional, Talhouk, Aline, additional, Unkila-Kallio, Leila, additional, van Meurs, Hannah S., additional, Yang, Winnie, additional, Rozenberg, Nirit, additional, Andersson, Noora, additional, Zaby, Katharina, additional, Bryk, Saara, additional, Bützow, Ralf, additional, Halfwerk, Johannes B. G., additional, Hooijer, Gerrit K. J., additional, van de Vijver, Marc J., additional, Buist, Marrije R., additional, Kenter, Gemma G., additional, Brucker, Sara Y., additional, Krämer, Bernhard, additional, Staebler, Annette, additional, Bleeker, Maaike C. G., additional, Heikinheimo, Markku, additional, Kommoss, Stefan, additional, Blake Gilks, C., additional, Anttonen, Mikko, additional, and Huntsman, David G., additional

Published
2016
Full Text
View/download PDF

228. Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study).

Author

Hahnen, Eric, primary, Baumann, Klaus H., additional, Heimbach, Andre, additional, Reuss, Alexander, additional, Jackisch, Christian, additional, Hauke, Jan, additional, Park-Simon, Tjoung-Won, additional, Richters, Lisa Katharina, additional, Hanker, Lars Christian, additional, Kroeber, Sandra, additional, Pfisterer, Jacobus, additional, Gevensleben, Heidrun, additional, Schnelzer, Andreas, additional, Dietrich, Dimo, additional, Schneider, Stephanie, additional, Kommoss, Stefan, additional, Marme, Frederic, additional, Prieske, Katharina, additional, Schmutzler, Rita K., additional, and Harter, Philipp, additional

Published
2016
Full Text
View/download PDF

229. Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1).

Author

Harter, Philipp, primary, Hauke, Jan, additional, Heitz, Florian, additional, Reuss, Alexander, additional, Kommoss, Stefan, additional, Marme, Frederik, additional, Heimbach, Andre, additional, Prieske, Katharina, additional, Richters, Lisa Katharina, additional, Burges, Alexander, additional, Neidhardt, Guido, additional, de Gregorio, Nikolaus, additional, El-Balat, Ahmed, additional, Hilpert, Felix, additional, Meier, Werner, additional, Heubner, Martin Leonhard, additional, Kast, Karin, additional, Braicu, Ioana, additional, Hahnen, Eric, additional, and Schmutzler, Rita K., additional

Published
2016
Full Text
View/download PDF

230. Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction

Author

Talhouk, Aline, primary, Kommoss, Stefan, additional, Mackenzie, Robertson, additional, Cheung, Martin, additional, Leung, Samuel, additional, Chiu, Derek S., additional, Kalloger, Steve E., additional, Huntsman, David G., additional, Chen, Stephanie, additional, Intermaggio, Maria, additional, Gronwald, Jacek, additional, Chan, Fong C., additional, Ramus, Susan J., additional, Steidl, Christian, additional, Scott, David W., additional, and Anglesio, Michael S., additional

Published
2016
Full Text
View/download PDF

231. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment

Author

Vogel, Rachel Isaksson, primary, Pulver, Tanya, additional, Heilmann, Wiebke, additional, Mooneyham, Ashley, additional, Mullany, Sally, additional, Zhao, Xianda, additional, Shahi, Maryam, additional, Richter, James, additional, Klein, Molly, additional, Chen, Liqiang, additional, Ding, Rui, additional, Konecny, Gottfried, additional, Kommoss, Stefan, additional, Winterhoff, Boris, additional, Ghebre, Rahel, additional, and Bazzaro, Martina, additional

Published
2016
Full Text
View/download PDF

232. Editorial

Author

Kommoss, Stefan, additional, Taran, Florin-Andrei, additional, and Wallwiener, Diethelm, additional

Published
2016
Full Text
View/download PDF

235. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Author

Mackenzie, Robertson, Mackenzie, Robertson, Kommoss, Stefan, Winterhoff, Boris J, Kipp, Benjamin R, Garcia, Joaquin J, Voss, Jesse, Halling, Kevin, Karnezis, Anthony, Senz, Janine, Yang, Winnie, Prigge, Elena-Sophie, Reuschenbach, Miriam, Doeberitz, Magnus Von Knebel, Gilks, Blake C, Huntsman, David G, Bakkum-Gamez, Jamie, McAlpine, Jessica N, Anglesio, Michael S, Mackenzie, Robertson, Mackenzie, Robertson, Kommoss, Stefan, Winterhoff, Boris J, Kipp, Benjamin R, Garcia, Joaquin J, Voss, Jesse, Halling, Kevin, Karnezis, Anthony, Senz, Janine, Yang, Winnie, Prigge, Elena-Sophie, Reuschenbach, Miriam, Doeberitz, Magnus Von Knebel, Gilks, Blake C, Huntsman, David G, Bakkum-Gamez, Jamie, McAlpine, Jessica N, and Anglesio, Michael S

Abstract

BackgroundMucinous ovarian tumors represent a distinct histotype of epithelial ovarian cancer. The rarest (2-4 % of ovarian carcinomas) of the five major histotypes, their genomic landscape remains poorly described. We undertook hotspot sequencing of 50 genes commonly mutated in human cancer across 69 mucinous ovarian tumors. Our goals were to establish the overall frequency of cancer-hotspot mutations across a large cohort, especially those tumors previously thought to be "RAS-pathway alteration negative", using highly-sensitive next-generation sequencing as well as further explore a small number of cases with apparent heterogeneity in RAS-pathway activating alterations.MethodsUsing the Ion Torrent PGM platform, we performed next generation sequencing analysis using the v2 Cancer Hotspot Panel. Regions of disparate ERBB2-amplification status were sequenced independently for two mucinous carcinoma (MC) cases, previously established as showing ERBB2 amplification/overexpression heterogeneity, to assess the hypothesis of subclonal populations containing either KRAS mutation or ERBB2 amplification independently or simultaneously.ResultsWe detected mutations in KRAS, TP53, CDKN2A, PIK3CA, PTEN, BRAF, FGFR2, STK11, CTNNB1, SRC, SMAD4, GNA11 and ERBB2. KRAS mutations remain the most frequently observed alteration among MC (64.9 %) and mucinous borderline tumors (MBOT) (92.3 %). TP53 mutation occurred more frequently in carcinomas than borderline tumors (56.8 % and 11.5 %, respectively), and combined IHC and mutation data suggest alterations occur in approximately 68 % of MC and as many as 20 % of MBOT. Proven and potential RAS-pathway activating changes were observed in all but one MC. Concurrent ERBB2 amplification and KRAS mutation were observed in a substantial number of cases (7/63 total), as was co-occurrence of KRAS and BRAF mutations (one case). Microdissection of ERBB2-amplified regions of tumors harboring KRAS mutation suggests these alterations are occurring in

Published
2015

236. Dual loss of theSWI/SNFcomplexATPases SMARCA4/BRG1andSMARCA2/BRMis highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type

Author

Karnezis, Anthony N, primary, Wang, Yemin, additional, Ramos, Pilar, additional, Hendricks, William PD, additional, Oliva, Esther, additional, D'Angelo, Emanuela, additional, Prat, Jaime, additional, Nucci, Marisa R, additional, Nielsen, Torsten O, additional, Chow, Christine, additional, Leung, Samuel, additional, Kommoss, Friedrich, additional, Kommoss, Stefan, additional, Silva, Annacarolina, additional, Ronnett, Brigitte M, additional, Rabban, Joseph T, additional, Bowtell, David D, additional, Weissman, Bernard E, additional, Trent, Jeffrey M, additional, Gilks, C Blake, additional, and Huntsman, David G, additional

Published
2015
Full Text
View/download PDF

237. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers

Author

Mackenzie, Robertson, primary, Talhouk, Aline, additional, Eshragh, Sima, additional, Lau, Sherman, additional, Cheung, Daphne, additional, Chow, Christine, additional, Le, Nhu, additional, Cook, Linda S., additional, Wilkinson, Nafisa, additional, McDermott, Jacqueline, additional, Singh, Naveena, additional, Kommoss, Friedrich, additional, Pfisterer, Jacobus, additional, Huntsman, David G., additional, Köbel, Martin, additional, Kommoss, Stefan, additional, Gilks, C. Blake, additional, and Anglesio, Michael S., additional

Published
2015
Full Text
View/download PDF

238. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Author

Rambau, Peter F, Vierkant, Robert A, Intermaggio, Maria P, Kelemen, Linda E, Goodman, Marc T, Herpel, Esther, Pharoah, Paul D, Kommoss, Stefan, Jimenez‐Linan, Mercedes, Karlan, Beth Y, Gentry‐Maharaj, Aleksandra, Menon, Usha, Polo, Susanna Hernando, Candido dos Reis, Francisco J, Doherty, Jennifer Anne, Gayther, Simon A, Sharma, Raghwa, Larson, Melissa C, Harnett, Paul R, and Hatfield, Emma

Abstract

We aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

239. DICER1and FOXL2Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors

Author

Karnezis, Anthony N., Wang, Yemin, Keul, Jacqueline, Tessier-Cloutier, Basile, Magrill, Jamie, Kommoss, Stefan, Senz, Janine, Yang, Winnie, Proctor, Lily, Schmidt, Dietmar, Clement, Philip B., Gilks, C. Blake, Huntsman, David G., and Kommoss, Friedrich

Abstract

Supplemental Digital Content is available in the text.Sertoli-Leydig cell tumors (SLCTs) are rare ovarian sex cord-stromal neoplasms. The only known recurrent genetic abnormality is DICER1mutation, with rare mutations reported in FOXL2. We set out to establish a molecular classifier using DICER1and FOXL2somatic mutation status and clinicopathologic features in 42 SLCTs. Five tumors (12%) were well differentiated, 31 (74%) moderately differentiated, and 6 (14%) poorly differentiated. Eight (19%) had heterologous elements, and 2 (5%) showed retiform differentiation; all 10 were moderately differentiated. DICER1RNase IIIb domain mutations were identified in 18/41 (44%; 17 moderately, 1 poorly differentiated), including all cases with retiform or heterologous elements. FOXL2c.402C>G(p.C134W) mutation was identified in 8/42 (19%) tumors (5 moderately, 3 poorly differentiated). DICER1and FOXL2mutations were mutually exclusive. Median age for the cohort was 47 years (range, 15 to 90 y). Patients with DICER1mutations were younger (median, 24.5 y; range, 15 to 62 y) than patients with FOXL2mutation (median, 79.5 y; range, 51 to 90 y) (P<0.0001). Nine of 10 tumors with retiform or heterologous elements occurred in premenopausal patients (median, 26.5 y; range, 15 to 57 y). Patients with tumors that were wild type for DICER1and FOXL2(15/42, 37%) had an intermediate age (median, 51 y; range, 17 to 74 y). All tumors were FOXL2 positive by immunohistochemistry. Patients with FOXL2mutation trended toward presenting more often with abnormal bleeding (P=0.13); DICER1-mutant patients trended toward having more androgenic symptoms (P=0.22). Our data suggest at least 3 molecular subtypes of SLCT with distinct clinicopathologic features: DICER1mutant (younger, more androgenic symptoms, moderately/poorly differentiated, retiform or heterologous elements), FOXL2mutant (postmenopausal, abnormal bleeding, moderately/poorly differentiated, no retiform or heterologous elements), and DICER1/FOXL2wild type (intermediate age, no retiform or heterologous elements, including all well-differentiated tumors).

Published
2019
Full Text
View/download PDF

240. An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer...

Author

Plante, Marie, Kwon, Janice S., Ferguson, Sarah, Samouëlian, Vanessa, Ferron, Gwenael, Maulard, Amandine, de Kroon, Cor, Van Driel, Willemien, Tidy, John, Marth, Christian, Tamussino, Karl, Kommoss, Stefan, Goffin, Frederic, Eyjólfsdóttir, Brynhildur, Kim, Jae-Weon, Gleeson, Noreen, Ubi, Juliana M, Brotto, Lori, Tu, Dongsheng, and Shepherd, Lois E.

Published
2023
Full Text
View/download PDF

241. The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN14 2): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.

Author

Kaya, Merve, Horeweg, Nanda, Leary, Alexandra, Welch, Stephen, Kommoss, Stefan, Weidner, Nicola, Fanfani, Francesco, Lorusso, Domenica, McGrane, John, Van Gorp, Toon, Boere, Ingrid, Westermann, Anneke M., Heijns, Joan B., Putter, Hein, Verhoeven-Adema, Karen, Smit, Vincent T.H.B.M., Creutzberg, Carien L., Bosse, Tjalling, and Kroep, Judith R.

Published
2023
Full Text
View/download PDF

242. Uterine sarcoma patients who underwent morcellation: Who are they? Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA- NOGGO RU1).

Author

Roser, Eva, Mirbach, Rebecca, Reichardt, Peter, Zocholl, Dario, Klar, Maximillian, Harter, Philipp, Kommoss, Stefan, Ulrich, Uwe Andreas, Mustea, Alexander, Wimberger, Pauline, Weigel, Michael, Frank, Matthias, Schmalfeldt, Barbara, Hanker, Lars Ch., Flörcken, Anne, Arndt, Tjadina, Pietzner, Klaus, and Sehouli, Jalid

Published
2023
Full Text
View/download PDF

243. Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.

Author

Mirza, Mansoor Raza, Powell, Matthew A., Lundgren, Caroline, Sukhin, Vladyslav, Pothuri, Bhavana, Gilbert, Lucy, Gill, Sarah, Ronzino, Graziana, Nevadunsky, Nicole, Kommoss, Stefan, Willmott, Lyndsay, Boere, Ingrid, Mathews, Cara Amanda, Buscema, Joseph, Teneriello, Michael, Shahin, Mark S., Meyers, Oren, Garside, Jamie, Coleman, Robert L., and Slomovitz, Brian M.

Published
2023
Full Text
View/download PDF

244. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma

Author

Hoang, Lien N., primary, McConechy, Melissa K., additional, Köbel, Martin, additional, Anglesio, Michael, additional, Senz, Janine, additional, Maassen, Malden, additional, Kommoss, Stefan, additional, Meng, Bo, additional, Postovit, Lynne, additional, Kelemen, Linda E., additional, Staebler, Annette, additional, Brucker, Sara, additional, Krämer, Bernhard, additional, McAlpine, Jessica N., additional, Gilks, C. Blake, additional, Huntsman, David G., additional, and Lee, Cheng-Han, additional

Published
2015
Full Text
View/download PDF

245. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study

Author

Fotopoulou, Christina, primary, Sehouli, Jalid, additional, Ewald-Riegler, Nina, additional, de Gregorio, Nikolaus, additional, Reuss, Alexander, additional, Richter, Rolf, additional, Mahner, Sven, additional, Kommoss, Friedrich, additional, Schmalfeldt, Barbara, additional, Fehm, Tanja, additional, Hanker, Lars, additional, Wimberger, Pauline, additional, Canzler, Ulrich, additional, Pfisterer, Jacobus, additional, Kommoss, Stefan, additional, Hauptmann, Steffen, additional, and du Bois, Andreas, additional

Published
2015
Full Text
View/download PDF

246. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality

Author

Anglesio, Michael S., primary, Wang, Yi Kan, additional, Maassen, Madlen, additional, Horlings, Hugo M., additional, Bashashati, Ali, additional, Senz, Janine, additional, Mackenzie, Robertson, additional, Grewal, Diljot S., additional, Li-Chang, Hector, additional, Karnezis, Anthony N., additional, Sheffield, Brandon S., additional, McConechy, Melissa K., additional, Kommoss, Friedrich, additional, Taran, Florin A., additional, Staebler, Annette, additional, Shah, Sohrab P., additional, Wallwiener, Diethelm, additional, Brucker, Sara, additional, Gilks, C. Blake, additional, Kommoss, Stefan, additional, and Huntsman, David G., additional

Published
2015
Full Text
View/download PDF

247. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Author

Davis, Sally J., primary, Sheppard, Karen E., additional, Anglesio, Michael S., additional, George, Joshy, additional, Traficante, Nadia, additional, Fereday, Sian, additional, Intermaggio, Maria P., additional, Menon, Usha, additional, Gentry-Maharaj, Aleksandra, additional, Lubinski, Jan, additional, Gronwald, Jacek, additional, Pearce, Celeste Leigh, additional, Pike, Malcolm C., additional, Wu, Anna, additional, Kommoss, Stefan, additional, Pfisterer, Jacobus, additional, du Bois, Andreas, additional, Hilpert, Felix, additional, Ramus, Susan J., additional, Bowtell, David D.L., additional, Huntsman, David G., additional, Pearson, Richard B., additional, Simpson, Kaylene J., additional, Campbell, Ian G., additional, and Gorringe, Kylie L., additional

Published
2015
Full Text
View/download PDF

248. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms

Author

Mackenzie, Robertson, primary, Kommoss, Stefan, additional, Winterhoff, Boris J., additional, Kipp, Benjamin R., additional, Garcia, Joaquin J., additional, Voss, Jesse, additional, Halling, Kevin, additional, Karnezis, Anthony, additional, Senz, Janine, additional, Yang, Winnie, additional, Prigge, Elena-Sophie, additional, Reuschenbach, Miriam, additional, Doeberitz, Magnus Von Knebel, additional, Gilks, Blake C., additional, Huntsman, David G., additional, Bakkum-Gamez, Jamie, additional, McAlpine, Jessica N., additional, and Anglesio, Michael S., additional

Published
2015
Full Text
View/download PDF

250. Aktuelle Studien zum Ovarialkarzinom

Author

Mahner, Sven, primary, Wölber, Linn, additional, von Amsberg, Gunhild, additional, Hilpert, Felix, additional, Baumann, Klaus, additional, Kommoss, Stefan, additional, de Gregorio, Nikolaus, additional, Harter, Philipp, additional, and Trillsch, Fabian, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results